MGMT and glioblastoma: Therefore, it is important to identify significant prognostic biomarkers, such as mutations in isocitrate dehydrogenase (IDH) and O6-methylguanine-methyltransferase (MGMT) promoter methylation, to improve the prognosis for GBM patients.